Patent ID: 7759359

Claim:
A method for treating a bladder dysfunction in a patient comprising orally administering to a patient suffering from a bladder dysfunction a once-a-day dosage formulation of a pharmaceutically acceptable salt of trospium (Tr + ) comprising at least one component selected from the group consisting of an extended release (XR) and a delayed release (DR) component; wherein at least a portion of said formulation releases trospium chloride in the lower gastrointestinal (GI) tract; which formulation provides an average Cmax at steady state of less than 2400 pg/ml of Tr + at a Tmax of less than 6 hours; and wherein the bladder dysfunction is selected from the group consisting of urinary frequency, urgency, nocturia, urge-incontinence associated with detrusor instability, urge syndrome, and detrusor hyperreflexia.